Broughton's Toxicology Managing Consultant Dr. Tony Jones summarizes the highlights and key takeaway messages from the Respiratory Drug Delivery conference (RDD).
Broughton expands its nicotine services business
Mar 21, 2019 | Published by Dr. Paul Moran
We are delighted to officially announce the recent launch of Broughton Limited, a spin-off from the long-established Broughton. The new company will specialize in accelerating safer nicotine-delivery products to market; advancing a smoke-free future.
This launch coincides with the development of a brand-new 15,000 ft2 CRO facility in Lancashire, designed specifically to address the needs of the Electronic Nicotine Delivery Systems (ENDS) market. As we’ve operated in this rapidly expanding and changing market for almost 10 years, we’re now perfectly placed to guide ENDS companies through the current period of growth and regulatory change.
Over £5M was raised in 2018 to invest in the new facility, which includes several specialist laboratories equipped with the latest aerosol collection instruments, high-spec analytical equipment and fully validated software data management systems. An impressive stand-alone stability facility covering all ICH storage requirements is also included in this initial phase of developments. Led by our growing team of experienced scientists and analytical chemists, the operation is aligned with capacity for further expansion during 2019, to meet the expectations of our global client base.
''We have seen rapid change over recent years within the reduced-risk nicotine products market. At Broughton , we are committed to supporting this evolving industry towards creating a smoke-free future through innovations, scientific advancement and regulatory compliance. Operating as an independent company within the Broughton Group, specializing in next generation nicotine delivery, will enable us to continue to accelerate the transformation of this exciting industry for our clients''.
Dr Paul Moran, Chief Executive.